TMCI
Treace Medical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TMCI
Treace Medical Concepts, Inc.
A medical technology company driving a fundamental shift in the surgical treatment of hallux valgus
Healthcare Equipment and Supplies
--
04/23/2021
NASDAQ Stock Exchange
477
12-31
Common stock
100 Palmetto Park Place, Ponte Vedra, Florida 32081
--
Treace Medical Concepts, Inc., was incorporated in Delaware in July 2013. The company is a medical technology company with the goal of improving the standard of care for surgical treatment of bunions and related midfoot deformities. The company pioneered the proprietary Lapiplasty 3 D bunion correction system — a technology that combines instruments, implants and surgical methods to surgically correct bunion deformities at all three levels. In order to provide a solution to solve midfoot deformities at the same time, in 2021, the company launched the Adductoplasty System, which combines implants and precision instruments for the first comprehensive system design for readjustable, stabilized and fused midfoot.
Earnings Call
Q1/2025
Estimate EPS-0.3
Actual EPS-0.25
Estimate Revenue52.07M
Actual Revenue52.60M
Treace Medical Concepts' Q1 2025: Navigating Contradictions in Competitive Positioning, Revenue Growth, and Cash Management
May 19,2025 12:33
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.29
Actual EPS-0.28
Estimate Revenue47.08M
Actual Revenue47.39M
Treace Medical Concepts' Q2 2025: Dissecting Contradictions in Growth, Product Reception, and Market Strategies
Aug 08,2025 06:21
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.27
Actual EPS-0.26
Estimate Revenue49.60M
Actual Revenue50.20M
Treace Medical's Q3 2025 Earnings Call: Contradictions Emerge on Strategy, Growth, and Market Share Amid Lapiplasty and MIS Osteotomy Shifts
Nov 09,2025 03:31
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TMCI has released its 2025 Q3 earnings. EPS was reported at -0.26, versus the expected -0.27, beating expectations. The chart below visualizes how TMCI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TMCI has released its 2025 Q3 earnings report, with revenue of 50.21M, reflecting a YoY change of 11.37%, and net profit of -16.29M, showing a YoY change of -6.04%. The Sankey diagram below clearly presents TMCI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
